us en false false Default
Skip directly to Accessibility Notice
PPH VanEck Pharmaceutical ETF Please read important disclosure Close important disclosure Show More Show Less Compare false

PPH
VanEck Pharmaceutical ETF

PPH
VanEck Pharmaceutical ETF

  • NAV
    $121.58

    as of November 10, 2026
  • YTD RETURNS
    19.93%

    as of November 10, 2026
  • Total Net Assets
    $1.09B

    as of November 10, 2026
  • Total Expense Ratio
    0.36%
  • Inception Date
    12/20/2011

Overview

Why PPH

  • Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
  • Industry LeadersFavors established industry leaders with meaningful scale
  • Global ScopeProvides exposure to U.S. and international equities for global industry representation

VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

Performance

Average Annual Total Returns* (%)

  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE 12/20/11
PPH (NAV) 9.48 8.49 17.71 31.59 18.94 11.85 10.78 10.62
PPH (Market Price) 9.37 8.45 17.66 31.57 18.95 11.84 10.78 10.69
MVIS US Listed Pharmaceutical 25 Index 9.49 8.52 17.51 31.39 18.58 11.49 10.51 10.43
  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE 12/20/11
PPH (NAV) -3.28 0.50 7.51 23.60 13.35 10.67 8.69 10.00
PPH (Market Price) -3.19 0.67 7.58 23.72 13.37 10.65 8.70 10.09
MVIS US Listed Pharmaceutical 25 Index -3.26 0.55 7.32 23.42 13.00 10.31 8.44 9.81

Holdings

Daily Holdings (%) as of 11/10/2026

Download XLS Get holdings
Total Holdings: 26
Ticker
Holding Name
% of Net Assets
Market Value (US$)
LLY
Eli Lilly & Co
23.05
251,836,686
MRK
Merck & Co Inc
12.21
133,417,478
NVO
Novo Nordisk A/S
5.41
59,109,221
MCK
Mckesson Corp
4.94
53,997,424
PFE
Pfizer Inc
4.78
52,226,654
TEVA
Teva Pharmaceutical Industries Ltd
4.58
50,030,558
BMY
Bristol-Myers Squibb Co
4.41
48,181,228
COR
Cencora Inc
4.39
47,966,804
GSK
Gsk Plc
4.29
46,852,192
AZN
Astrazeneca Plc
3.72
40,694,444
NVS
Novartis Ag
3.72
40,608,803
ABBV
Abbvie Inc
3.67
40,053,093
SNY
Sanofi Sa/France
3.52
38,488,456
HLN
Haleon Plc
3.34
36,527,302
JNJ
Johnson & Johnson
3.29
35,949,948
TAK
Takeda Pharmaceutical Co Ltd
2.81
30,672,455
ZTS
Zoetis Inc
2.63
28,691,050
VTRS
Viatris Inc
1.59
17,357,396
JAZZ
Jazz Pharmaceuticals Plc
1.26
13,755,615
ELAN
Elanco Animal Health Inc
0.53
5,842,752
AXSM
Axsome Therapeutics Inc
0.50
5,508,544
CORT
Corcept Therapeutics Inc
0.44
4,817,335
DFTX
Definium Therapeutics Inc
0.40
4,365,922
OGN
Organon & Co
0.26
2,877,202
PRGO
Perrigo Co Plc
0.11
1,194,896
-USD CASH-
--
0.00
9,775
--
Other/Cash
0.16
1,736,228
← Scroll for more information →
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Portfolio

Sector Weightings (%) as at 10/31/2026

  • Sector

    % of Net Assets
  • Health Care

    99.90
  • Other/Cash

    0.10

Country Weightings (%) as at 10/31/2026

  • Country

    % of Net Assets
  • United States

    68.70
  • United Kingdom

    11.27
  • Denmark

    5.42
  • Israel

    4.63
  • Switzerland

    3.73
  • France

    3.30
  • Japan

    2.86
  • Other/Cash

    0.10

Fees

Distributions

  as of  11/10/2026


Distribution Frequency

Quarterly


30-Day SEC Yield

1.58%


Distribution Yield

1.18%


12 Month Yield

1.76%

Yield information reflects temporary waivers of expenses and/or fees. Yields would have been reduced had these fees/expenses been included. In the absence of temporary expense waivers or reimbursements, the 30-Day SEC Yield for VanEck Pharmaceutical ETF would have been 1.58% on 11/10/26. Distributions may vary from time to time.

Team

Resources

PPH